View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Analysis
August 28, 2015

Pharma Technology Focus – Issue 38

In this issue: South Africa's long road to domestic manufacturing, the 21st Century Cures Act divides opinion in the US, closing the talent gap in contract research, the growing market for unlicensed drugs, and more.

By Susanne Hauner

Pharma Technology Focus

Pharma Technology Focus is now published monthly and free for the iPad. Download our app from Newsstand to read the latest issue and browse our back issues for free.

South Africa is looking to follow China’s lead by building state-owned pharma manufacturing capacity to help meet the needs of its health system with less reliance on foreign imports, but it has been a bumpy road so far. We find out how the country aims to reach its goal.

The 21st Century Cures Act is moving rapidly through the US legislative process but it continues to divide opinion among the healthcare community. We take a look at both sides of the argument. We also speak to Clinigen to find out how the company has carved out a niche in the ethical supply of unlicensed medicines and what lies ahead for this growing market.

Moreover, we learn why CROs need to rethink their recruitment strategies as demand for resources in clinical research grows, and we ask why the healthcare sector is increasingly tapping into the potential of gamification to improve adherence and build patient loyalty.

Read the issue for free on your iPad through our app, or if you’re on a desktop computer you can also read it in our web viewer.

In this issue

Pipeline: RSV Vaccines
Novavax’s RSV vaccine shines in phase II trials, but key challenges remain and competitors are hot on its heels, writes Moritz Herrmann, PhD, GlobalData analyst for infectious diseases.
Read the article.

The Long Road Ahead
South Africa wants to build state-owned domestic manufacturing capacity to help meet the needs of its healthcare system and reduce reliance on foreign imports. While the idea sounds good on paper, putting it into practice hasn’t been straightforward, as Elly Earls finds out.
Read the article.

Cure or Curse?
The 21st Century Cures Act is moving rapidly through the US legislative process, but critics remain skeptical of its benefits. Abi Millar explores both sides of the story.
Read the article.

Tapping the Talent Pool
As the demand for resource in clinical research grows, CROs need to rethink their roles and position themselves as more than transactional partners, writes Dr Martin Robinson, IAOCR executive vice president and ambassador.
Read the article.

Big Topics for 2015
CPhI offers a preview of its annual report for 2015, which will examine the latest trends to impact the pharma industry over the next few years.
Read the article.

Unlocking a New Market
As the demand for unlicensed medicines grows, Elly Earls asks Clinigen COO Shaun Chilton and Frost & Sullivan analyst Barbara Gilmore about the opportunities and challenges of this fast-growing market.
Read the article.

Spotlight on axSpA
With awareness of axial spondyloarthritis on the rise and novel therapies well within reach, this disease has come into the spotlight. GlobalData senior analysts for immunology Heather Leach, PhD, and Eirini Vavatsikou, PhD report from this year’s European League Against Rheumatism (EULAR) conference in Rome.
Read the article.

The Game is On
In the search for new ways to improve adherence, the industry is turning to smartphone games to remind patients of their treatment regimes. Dr Nicola Davies explores the benefits of the ‘gamification’ of healthcare.
Read the article.

Next issue preview

Scientists in Scotland have discovered an anti-malarial compound that could eventually treat the disease and prevent its transmission with a dose that costs just $1. We look into this promising research and find out whether it could turn a new page for malaria treatment.

While the threat of antimicrobial resistance continues to grow, antibiotics innovation has stalled due to a lack investment. We ask what can be done to attract much-needed funds to this vital area of drug development. We also investigate why Parkinson’s trails continue to suffer from low success rates, and review research suggesting that statins could find a new application in improving cancer survival rates.

Moreover, we find out how London Mayor Boris Johnson aims to attract pharma business to the city with a £10bn ‘megafund’, and investigate what a British exit from the EU could mean for the country’s pharma companies and their European counterparts.

Digital magazine FAQ

You can read Pharma Technology Focus for free on the iPad. Download our app from the App Store to read the latest issue and browse the back issues in our archive. Sign up for a free subscription in the app and never miss a new issue.

You can also continue to read the desktop version for free on our web viewer. (Browser compatibility: The web viewer works in the latest two version of Chrome, Firefox and Safari, as well as in Internet Explorer 9 and 10. Some features may not be compatible with older browser versions.)

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU